Viromed Medical H1 FY26 net loss widens to €1.1 million, revenue rises 4.17%
Revenue rose to €2.5 million from a year earlier, while equity climbed to €9.5 million and the equity ratio improved to 67.6%. Management reaffirmed full-year 2026 guidance for a significant increase in revenue and net income.